In an interview conducted by EMJ, a leading expert from the field of cardiology and cardiovascular disease provided their perspectives on Phase II data and the design of the Phase II trial for aficamten. A cardiac myosin inhibitor, aficamten targets the underlying pathophysiology of hypertrophic cardiomyopathy.
EMJ Cardiology 10 [Supplement 1] . 2022
June 2022
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/06/Innov-Article-Congenital-Heart-Disease-and-Autism-Spectrum-Disorder-web-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/06/Cardio-Article-Endovascular-Stenting-for-Superior-Vena-Cava-Syndrome-web-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/04/Cardio-12.1-Interview-David-Fischman-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/01/Interview-940x564.png)